Sernova Biotherapeutics Inc (GETTEX:PSH0) Financings

Sernova Biotherapeutics Inc

Financings

RaiseDateIn US dollars
Convertible notes and common stock purchase warrants of Seraxis
Closed: US$11.2M raised
Buyers: Dr. Steven Sangha / Arlo Investments; Jonathan Rigby; Will Rust
Insiders: Insiders participated, including Dr. Steven Sangha / Arlo Investments, Sernova management and Seraxis management
Use of proceeds: cGMP manufacturing of SR-02 islet cells and enrollment of T1D patients for the Phase 1/2 clinical trial
Oct 5, 2026
Unsecured convertible debentures
Closed: C$1.5M raised · C$0.15 · Warrants at C$0.25 for 36 months
Insiders: Financing made with an insider; insiders participated, treated as related party transactions
Apr 23, 2026US$1.1M
Private placement of units
Closed: C$4M raised
Insiders: Unit financing made with an insider; insiders participated, treated as related party transactions
Use of proceeds: To retire outstanding loan obligations
Apr 23, 2026US$2.92M
Private placement of units
Update: C$4M · C$0.15 a unit · 1 warrant at C$0.2 for 36 months
Insiders: Shareholders approved the issuance of the units to an insider of the Company
Use of proceeds: Retire the existing $4.0 million secured term loan maturing April 16, 2026
Apr 9, 2026US$2.93M
Private placement of units
Announced: C$1.6M · C$0.15 a unit · 1 warrant at C$0.25 for 36 months
Mar 4, 2026US$1.17M
Private placement of units
Tranche closed: C$874,600 raised · C$0.16 a unit · 1 warrant at C$0.4 for 36 months
Use of proceeds: General operating capital and launch of final Cohort C in the Phase 1/2 trial of its Cell Pouch Bio-hybrid Organ for type 1 diabetes
Nov 13, 2025US$623,912
Unsecured convertible debenture
Closed: C$1M raised · Warrants at C$0.2
Buyers: Dr. Steven Sangha (CAD$1,000,000 unsecured convertible debenture and 5,000,000 warrants)
Insiders: The debenture and warrants were issued to Dr. Steven Sangha, a shareholder and board member; a related party transaction under MI 61-101
Use of proceeds: Working capital
Mar 5, 2025US$695,894

Read by 6ix AI from the company's releases